Iron overload phenotypes and HFE genotypes in white hemochromatosis and iron overload screening study participants without HFE p.C282Y/p.C282Y.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
03
2022
accepted:
11
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
30
7
2022
Statut:
epublish
Résumé
Screening program participants with iron overload (IO) phenotypes without HFE p.C282Y/p.C282Y are incompletely characterized. We studied white participants who had IO phenotypes without p.C282Y/p.C282Y in post-screening clinical examinations (CE). We defined IO phenotypes as a) elevated serum ferritin (SF) and transferrin saturation (TS) at screening and CE, and b) absence of IO treatment, anemia, transfusion >10 units, alcohol intake >30 g/d, hepatitis B or C, and pregnancy. We defined IO-related disease as elevated alanine or aspartate aminotransferase (ALT/AST) or swelling/tenderness of 2nd/3rd metacarpophalangeal (MCP) joints. All participants had HFE p.C282Y and p.H63D genotyping. There were 32 men and 26 women (mean age 54±16 y). Median food/supplemental iron intakes were 14.3/0.0 mg/d. Relative risks of HFE genotypes were 12.9 (p.C282Y/p.H63D), 3.0 (p.H63D/p.H63D), 1.9 (p.C282Y/wt), 0.9 (p.H63D/wt), and 0.5 (wt/wt) compared to 42,640 white screening participants without IO phenotypes or p.C282Y/p.C282Y. Regression on SF revealed positive associations: MCV (p = 0.0006; β coefficient = 0.4531); swelling/tenderness of MCP joints (p = 0.0033; β = 0.3455); and p.H63D/wt (p = 0.0015; β = 0.4146). IO-related disease (18 elevated ALT/AST, one swelling/tenderness of MCP joints) occurred in 19 participants (7 men, 12 women). Median MCV was higher in participants with IO-related disease (97 fL vs. 94 fL; p = 0.0007). Logistic regression on IO-related disease revealed a significant association with diabetes (p = 0.0416; odds ratio 18.9 (95% confidence interval 1.0, 341.1)). In the present 58 screening program participants who had IO phenotypes without HFE p.C282Y/p.C282Y, relative risks of HFE genotypes p.C282Y/p.H63D, p.H63D/p.H63D, and p.C282Y/wt were significantly higher than in 42,640 white screening participants with neither IO phenotypes nor p.C282Y/p.C282Y. SF was significantly associated with MCV, swelling/tenderness of 2nd/3rd MCP joints, and p.H63D/wt. IO-related disease was significantly associated with MCV and diabetes.
Sections du résumé
BACKGROUND
Screening program participants with iron overload (IO) phenotypes without HFE p.C282Y/p.C282Y are incompletely characterized.
METHODS
We studied white participants who had IO phenotypes without p.C282Y/p.C282Y in post-screening clinical examinations (CE). We defined IO phenotypes as a) elevated serum ferritin (SF) and transferrin saturation (TS) at screening and CE, and b) absence of IO treatment, anemia, transfusion >10 units, alcohol intake >30 g/d, hepatitis B or C, and pregnancy. We defined IO-related disease as elevated alanine or aspartate aminotransferase (ALT/AST) or swelling/tenderness of 2nd/3rd metacarpophalangeal (MCP) joints. All participants had HFE p.C282Y and p.H63D genotyping.
RESULTS
There were 32 men and 26 women (mean age 54±16 y). Median food/supplemental iron intakes were 14.3/0.0 mg/d. Relative risks of HFE genotypes were 12.9 (p.C282Y/p.H63D), 3.0 (p.H63D/p.H63D), 1.9 (p.C282Y/wt), 0.9 (p.H63D/wt), and 0.5 (wt/wt) compared to 42,640 white screening participants without IO phenotypes or p.C282Y/p.C282Y. Regression on SF revealed positive associations: MCV (p = 0.0006; β coefficient = 0.4531); swelling/tenderness of MCP joints (p = 0.0033; β = 0.3455); and p.H63D/wt (p = 0.0015; β = 0.4146). IO-related disease (18 elevated ALT/AST, one swelling/tenderness of MCP joints) occurred in 19 participants (7 men, 12 women). Median MCV was higher in participants with IO-related disease (97 fL vs. 94 fL; p = 0.0007). Logistic regression on IO-related disease revealed a significant association with diabetes (p = 0.0416; odds ratio 18.9 (95% confidence interval 1.0, 341.1)).
CONCLUSIONS
In the present 58 screening program participants who had IO phenotypes without HFE p.C282Y/p.C282Y, relative risks of HFE genotypes p.C282Y/p.H63D, p.H63D/p.H63D, and p.C282Y/wt were significantly higher than in 42,640 white screening participants with neither IO phenotypes nor p.C282Y/p.C282Y. SF was significantly associated with MCV, swelling/tenderness of 2nd/3rd MCP joints, and p.H63D/wt. IO-related disease was significantly associated with MCV and diabetes.
Identifiants
pubmed: 35895739
doi: 10.1371/journal.pone.0271973
pii: PONE-D-22-07434
pmc: PMC9328571
doi:
Substances chimiques
HFE protein, human
0
Hemochromatosis Protein
0
Transferrin
0
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271973Subventions
Organisme : NHLBI NIH HHS
ID : N01HC05188
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC05185
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC05186
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CM007003
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC05189
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC05190
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC05191
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000032
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Detect Prev. 1985;8(1-2):297-302
pubmed: 3864536
Ann Hepatol. 2014 May-Jun;13(3):353-6
pubmed: 24756010
Gut. 2002 Nov;51(5):723-30
pubmed: 12377814
J Diabetes Complications. 1993 Oct-Dec;7(4):246-9
pubmed: 8219368
Hepatology. 2009 Jul;50(1):94-101
pubmed: 19554541
Sci Rep. 2021 Oct 28;11(1):21242
pubmed: 34711879
Am J Med Sci. 2003 Feb;325(2):53-62
pubmed: 12589228
Blood Cells Mol Dis. 1997 Aug;23(2):314-20
pubmed: 9410475
Am J Hematol. 2009 Nov;84(11):710-4
pubmed: 19787796
N Engl J Med. 2008 Jan 17;358(3):221-30
pubmed: 18199861
Clin Lab Haematol. 1981;3(1):35-44
pubmed: 7226720
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
Nat Genet. 1996 Aug;13(4):399-408
pubmed: 8696333
Eur J Haematol. 2007 Jan;78(1):66-71
pubmed: 17042772
J Cancer Res Ther. 2014 Jul-Sep;10(3):681-5
pubmed: 25313760
J Hepatol. 2010 Jul;53(1):3-22
pubmed: 20471131
Ann Intern Med. 2000 Sep 5;133(5):329-37
pubmed: 10979877
Haematologica. 2009 Mar;94(3):307-9
pubmed: 19252171
Blood Cells Mol Dis. 2020 Nov;85:102463
pubmed: 32652459
Blood. 1999 Apr 15;93(8):2502-5
pubmed: 10194428
Hepatology. 2011 Jul;54(1):328-43
pubmed: 21452290
Can J Gastroenterol. 2008 Nov;22(11):923-30
pubmed: 19018338
Genet Test. 2002 Winter;6(4):331-4
pubmed: 12537660
Ann Hepatol. 2017 Aug 8;16(5):802-811
pubmed: 28809726
Blood Cells Mol Dis. 1997;23(1):135-45; discussion 145a-b
pubmed: 9215758
N Engl J Med. 2005 Apr 28;352(17):1769-78
pubmed: 15858186
J Clin Gastroenterol. 2009 Jul;43(6):569-73
pubmed: 19359997
Am J Hematol. 2007 Oct;82(10):898-905
pubmed: 17597476
Haematologica. 2009 Mar;94(3):335-9
pubmed: 19176363
Int J Obes (Lond). 2008 Nov;32(11):1665-9
pubmed: 18779821
Am J Epidemiol. 2000 Feb 15;151(4):358-70
pubmed: 10695594
Ann Epidemiol. 2011 Jan;21(1):1-14
pubmed: 20800508
Can J Gastroenterol. 2012 Jun;26(6):345-9
pubmed: 22720276
J Hepatol. 1999 Apr;30(4):588-93
pubmed: 10207799
J Lab Clin Med. 2000 Jan;135(1):96-104
pubmed: 10638700
Hum Genet. 1997 Dec;101(3):271-6
pubmed: 9439654
Biosci Rep. 2015 Mar 31;35(3):
pubmed: 26182354
Hum Mol Genet. 2003 Sep 1;12(17):2241-7
pubmed: 12915468
Gut. 2001 Jun;48(6):836-42
pubmed: 11358905
Genet Test. 2005 Fall;9(3):231-41
pubmed: 16225403
Clin Gastroenterol Hepatol. 2006 Nov;4(11):1403-10
pubmed: 16979952
Hepatology. 2012 Jan;55(1):77-85
pubmed: 21953442
Gene. 2015 Dec 15;574(2):179-92
pubmed: 26456104
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):338-43
pubmed: 15528154
Genet Med. 2000 Sep-Oct;2(5):271-7
pubmed: 11399207
Ann Hepatol. 2015 May-Jun;14(3):348-53
pubmed: 25864215
Blood Cells Mol Dis. 1999 Jun-Aug;25(3-4):147-55
pubmed: 10575540
J Lab Clin Med. 2006 Apr;147(4):191-6
pubmed: 16581347